Drug intelligence / Profile preview

SPH1021

Development stage: Unknown
Lead developer: Shanghai Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SPH1021 is an orally bioavailable small molecule inverse agonist of the retinoic acid receptor-related orphan receptor gamma t (RORγt), currently under development by Shanghai Pharmaceuticals Holding Co., Ltd. RORγt is a master transcription factor essential for the differentiation of T helper 17 (Th17) cells and the production of pro-inflammatory cytokines, including IL-17A, IL-17F, and IL-22. By antagonizing RORγt activity, SPH1021 aims to suppress the Th17-mediated inflammatory response, providing a therapeutic approach for autoimmune and inflammatory conditions such as arthritis and psoriasis. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics.

Targets

RORγt

Beyond the preview

Go deeper on SPH1021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH1021.

Explore the full profile